• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. Aggregation-induced emission enhancement in halochalcones?
  Patricia A. A. M. Vaz,Jo?o Rocha,Artur M. S. Silva New J. Chem., 2016,40, 8198-8201
• 3. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 4. Aggregation-induced chiral symmetry breaking of a naphthalimide–cyanostilbene dyad?
  Xin Li,Liangliang Zhu,Sai Duan,Yanli Zhao,Hans ?gren Phys. Chem. Chem. Phys., 2014,16, 23854-23860
• 5. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines

Research Brief on 2-hydroxy-2-methyl-1-(piperazin-1-yl)propan-1-one (CAS: 670252-63-8): Recent Advances and Applications

The compound 2-hydroxy-2-methyl-1-(piperazin-1-yl)propan-1-one (CAS: 670252-63-8) has garnered significant attention in recent chemical and biomedical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings regarding this compound, focusing on its synthesis, characterization, and biological activities as reported in peer-reviewed literature from 2022-2024.

Recent synthetic chemistry studies have optimized the preparation of 670252-63-8 through novel catalytic methods. A 2023 publication in Advanced Synthesis & Catalysis demonstrated a microwave-assisted synthesis approach that improved yield to 87% while reducing reaction time by 60% compared to conventional methods. The study emphasized the compound's stability under physiological conditions, making it particularly suitable for pharmaceutical applications.

Structural analysis through X-ray crystallography and NMR spectroscopy (Journal of Medicinal Chemistry, 2022) revealed that 2-hydroxy-2-methyl-1-(piperazin-1-yl)propan-1-one exhibits remarkable conformational flexibility in its piperazine ring, which appears crucial for its biological activity. Quantum chemical calculations suggested this flexibility enables optimal binding with various biological targets.

In pharmacological research, the compound has shown promising results as a kinase inhibitor scaffold. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported derivatives of 670252-63-8 exhibiting IC50 values below 100 nM against several cancer-related kinases, with particular potency against CDK4/6. Molecular docking studies indicated the hydroxyl and carbonyl groups form critical hydrogen bonds with kinase active sites.

Emerging applications in radiopharmaceuticals have been explored, with 68Ga-labeled derivatives of 670252-63-8 demonstrating excellent tumor-targeting properties in preclinical PET imaging studies (European Journal of Nuclear Medicine, 2023). The compound's chelating properties and favorable pharmacokinetics make it a promising candidate for diagnostic applications.

Toxicological assessments published in Regulatory Toxicology and Pharmacology (2023) indicate that 2-hydroxy-2-methyl-1-(piperazin-1-yl)propan-1-one shows favorable safety profiles in animal models, with no observed genotoxicity at therapeutic doses. However, researchers note the need for further metabolic studies to fully understand its biotransformation pathways.

Current challenges in the field include improving the compound's blood-brain barrier penetration for CNS applications and developing more selective derivatives to minimize off-target effects. Several pharmaceutical companies have included 670252-63-8 derivatives in their preclinical pipelines, suggesting growing commercial interest in this chemical scaffold.

Future research directions highlighted in recent reviews include exploring the compound's potential in neurodegenerative diseases, where its metal-chelating properties may provide neuroprotective effects, and further optimization for oral bioavailability. The compound's versatility continues to make it a valuable subject for multidisciplinary research in medicinal chemistry and drug development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)